Table 2 Clinical features of patients with ERBB2 somatic mutations or ERBB2 amplification only in Geneplus cohort

From: Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients

Characteristics

ERBB2 oncogenic mutationa (n = 474)

ERBB2 amplification only (n = 175)

P value

Age, years

  

<0.01

 Mean (SD)

53.6 (12.8)

63.0 (9.5)

 

 Median (min-max)

54 (21-83)

63 (37-89)

 

Gender, n (%)

  

<0.001

 Male

163 (34.4)

120 (68.6)

 

 Female

311 (65.6)

55 (31.4)

 

Smoking, n (%)

  

<0.001

 Never

222 (78.7)

58 (49.6)

 

 Ever

60 (21.3)

59 (50.4)

 

 Unknown

192 (100)

58 (100)

 

Tumor stage, n (%)

  

0.04b

 I

34 (23.8)

5 (6.8)

 

 II

6 (4.2)

5 (6.8)

 

 III

19 (13.3)

9 (12.4)

 

 IV

84 (58.7)

54 (74.0)

 

 Unknown

331 (100)

102

 

Histology, n (%)

  

<0.001c

 Adenocarcinoma

412 (98.6)

123 (82.6)

 

 Squamous cell carcinoma

3 (0.7)

23 (15.4)

 

 Adenosquamous carcinoma

2 (0.5)

2 (1.3)

 

 Sarcomatoid carcinoma

1 (0.2)

0

 

 Neuroendocrine neoplasms

0

1 (0.7)

 

 Unknown

56 (100)

26

 

Germline mutation, n (%)

  

0.8

 Yes

14 (3.0)

6 (3.4)

 

 No

460 (97.0)

169 (96.6)

 

PD-L1 test, n (%)

  

0.8

 TPS < 1%

54 (63.5)

34 (58.6)

 

 TPS,1%-50%

26 (30.6)

19 (32.8)

 

 TPS ≥ 50%

5 (5.9)

5 (8.6)

 

 Unknown

389 (100)

117 (100)

 

TMB

  

<0.001

 Mean (SD)

3.5 (4.6)

8.9 (9.2)

 

 Median (min-max)

1.9 (0-28.8)

5.8 (0-68.0)

 
  1. aERBB2 oncogenic mutation includes ERBB2 oncogenic mutation accompanied with/without ERBB2 amplification.
  2. bComparison between I-III and IV.
  3. cComparison between adenocarcinoma and non-adenocarcinoma.